Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Targeting IDH2 R140Q and other neoantigens in acute myeloid leukemia

Wingchi K. Leung, Alejandro G. Torres Chavez, Matthew French-Kim, Paul Shafer, Maksim Mamonkin, LaQuisa C. Hill, Manik Kuvalekar, Yovana Velazquez, Ayumi Watanabe, Norihiro Watanabe, Valentina Hoyos, Premal Lulla, Ann M. Leen

Blood (2024) 143 (17): 1726–1737.

https://doi.org/10.1182/blood.2023021979

Published: 2024

Includes: Supplemental data

Journal Articles

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas

Blood (2024) 143 (13): 1231–1241.

https://doi.org/10.1182/blood.2023022204

Published: 2024

Includes: Supplemental data

Journal Articles

Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry

Blood (2023) 142 (Supplement 1): 1029.

https://doi.org/10.1182/blood-2023-177693

Published: 2023

Journal Articles

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Blood (2023) 142 (Supplement 1): 355.

https://doi.org/10.1182/blood-2023-181181

Published: 2023

Journal Articles

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

Blood (2022) 140 (1): 16–24.

https://doi.org/10.1182/blood.2022015728

Published: 2022

Journal Articles

COVID-specific T's may offset therapeutically endangered B's

LaQuisa C. Hill, Premal D. Lulla

Blood (2022) 139 (1): 12–13.

https://doi.org/10.1182/blood.2021014466

Published: 2022

Journal Articles

Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL

Blood (2021) 138 (Supplement 1): 471.

https://doi.org/10.1182/blood-2021-149332

Published: 2021

Journal Articles

Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma

Rayne H. Rouce, LaQuisa C. Hill, Tyler S. Smith, Lina Yang, Blakely Boriskie, Madhuwanti Srinivasan, Huimin Zhang, Silvana Perconti, Birju Mehta, Olga Dakhova, Bambi J. Grilley, Helen E. Heslop, Malcolm K. Brenner, Maksim Mamonkin

Blood (2021) 138 (Supplement 1): 654.

https://doi.org/10.1182/blood-2021-154142

Published: 2021

Journal Articles

Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19

Spyridoula Vasileiou, PhD, Manik Kuvalekar, Msc, Aster Workineh, Msc, Ayumi Watanabe, Bsc, Yovana Velazquez, Bsc, Suhasini Lulla, Bsc, Helen E. Heslop, MD DSc, Kimberly Mooney, Bsc, Kevin Grimes, MD, George Carrum, MD, LaQuisa C. Hill, MD, Premal Lulla, MBBS, Ann M. Leen, PhD

Blood (2020) 136 (Supplement 1): 5.

https://doi.org/10.1182/blood-2020-140490

Published: 2020

Journal Articles

Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies

LaQuisa C. Hill, MD, Rayne H. Rouce, MD, Tyler S. Smith, Lina Yang, PhD, Madhuwanti Srinivasan, Huimin Zhang, BS, Silvana Perconti, Birju Mehta, MS, BS, Olga Dakhova, Josalind Randall, Bambi J. Grilley, RPh, Helen E. Heslop, MD DSc, Malcolm K. Brenner, MD PhD, Maksim Mamonkin, PhD

Blood (2019) 134 (Supplement_1): 199.

https://doi.org/10.1182/blood-2019-129559

Published: 2019

Journal Articles

T Cell Immunity Toward Viral- and Tumor-Antigens Is Preserved in MDS Patients

Hussein Hamad, MD, Wingchi K Leung, MD, Spyridoula Vasileiou, PhD, Shivani Mukhi, Quillan Huang, MD, George Carrum, MD, Carlos A. Ramos, MD, Rammurti Kamble, MD, LaQuisa C. Hill, MD, Ann M. Leen, PhD, Premal Lulla, MBBS

Blood (2019) 134 (Supplement_1): 4225.

https://doi.org/10.1182/blood-2019-126792

Published: 2019

NARROW

Targeting IDH2 R140Q and other neoantigens in acute myeloid leukemia

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas

Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

COVID-specific T's may offset therapeutically endangered B's

Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL

Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma

Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19

Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies

T Cell Immunity Toward Viral- and Tumor-Antigens Is Preserved in MDS Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only